Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

A Novel Regimen for Acute Myeloid Leukemia with MLL Partial Tandem Duplication: Results of a Phase 1 Study NCI 8485

Alice S. Mims, MD MSCR, Rebecca B Klisovic, MD, Ramiro Garzon, MD, Alison R. Walker, MD MPH, Steven M. Devine, MD, Katherine J. Walsh, MD, Sumithira Vasu, MBBS, Susan P. Whitman, PhD, Guido Marcucci, MD, Nyla A. Heerema, PhD, Michael A. Caligiuri, MD, Clara D. Bloomfield, MD, John C. Byrd, MD, Richard Piekarz, PhD MD, Michael R. Grever, MD, William Blum, MD

Blood (2016) 128 (22): 900.

https://doi.org/10.1182/blood.V128.22.900.900

Published: 2016

Journal Articles

Decitabine enhances anti-CD33 monoclonal antibody BI 836858–mediated natural killer ADCC against AML blasts

Blood (2016) 127 (23): 2879–2889.

https://doi.org/10.1182/blood-2015-11-680546

Published: 2016

Includes: Supplemental data

Journal Articles

Eradicating acute myeloid leukemia in a Mll PTD/wt : Flt3 ITD/wt murine model: a path to novel therapeutic approaches for human disease

Blood (2013) 122 (23): 3778–3783.

https://doi.org/10.1182/blood-2013-06-507426

Published: 2013

Journal Articles

Differential Clinical Impact Of Gene Mutations and Their Combinations In Primary Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Blood (2013) 122 (21): 2540.

https://doi.org/10.1182/blood.V122.21.2540.2540

Published: 2013

Journal Articles

Decitabine Or 5-Azacitidine Pre-Treatment Does Not Compromise The Novel Fc-Engineered Antibody Mab 33.1-Mediated ADCC Against Primary AML Blasts - A Rationale For Combination Therapy

Shun He, PhD, Carolyn Cheney, Susan P. Whitman, PhD, Jianhua Yu, PhD, Sumithira Vasu, MBBS, William Blum, MD, Karl-Heinz Heider, PhD, Guido Marcucci, MD, Natarajan Muthusamy, DVM, Ph.D

Blood (2013) 122 (21): 3959.

https://doi.org/10.1182/blood.V122.21.3959.3959

Published: 2013

Journal Articles

Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target

Il-Kyoo Park, Anjali Mishra, Jason Chandler, Susan P. Whitman, Guido Marcucci, Michael A. Caligiuri

Blood (2013) 121 (11): 2064–2073.

https://doi.org/10.1182/blood-2012-07-444018

Published: 2013

Includes: Supplemental data

Journal Articles

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia

Blood (2013) 121 (1): 159–169.

https://doi.org/10.1182/blood-2012-05-428573

Published: 2013

Includes: Supplemental data

Journal Articles

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia

Blood (2012) 120 (12): 2466–2474.

https://doi.org/10.1182/blood-2012-05-429175

Published: 2012

Includes: Supplemental data

Journal Articles

Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias

Nicholas A. Zorko, Kelsie M. Bernot, Susan P. Whitman, Ronald F. Siebenaler, Elshafa H. Ahmed, Gabriele G. Marcucci, Daniel A. Yanes, Kathleen K. McConnell, Charlene Mao, Chidimma Kalu, Xiaoli Zhang, David Jarjoura, Adrienne M. Dorrance, Nyla A. Heerema, Benjamin H. Lee, Gang Huang, Guido Marcucci, Michael A. Caligiuri

Blood (2012) 120 (5): 1130–1136.

https://doi.org/10.1182/blood-2012-03-415067

Published: 2012

Journal Articles

Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells

Yue Zhang, Xiaomei Yan, Goro Sashida, Xinghui Zhao, Yalan Rao, Susumu Goyama, Susan P. Whitman, Nicholas Zorko, Kelsie Bernot, Rajeana M. Conway, David Witte, Qian-fei Wang, Daniel G. Tenen, Zhijian Xiao, Guido Marcucci, James C. Mulloy, H. Leighton Grimes, Michael A. Caligiuri, Gang Huang

Blood (2012) 120 (5): 1118–1129.

https://doi.org/10.1182/blood-2012-02-412379

Published: 2012

Includes: Supplemental data

Journal Articles

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia

Blood (2012) 120 (2): 249–258.

https://doi.org/10.1182/blood-2012-02-408492

Published: 2012

Includes: Supplemental data

Journal Articles

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

Blood (2011) 118 (26): 6920–6929.

https://doi.org/10.1182/blood-2011-08-368225

Published: 2011

Includes: Supplemental data

Journal Articles

MiR-3151 , a Novel MicroRNA Embedded in BAALC , Is Only Weakly Co-Expressed with Its Host Gene and Independently Impacts on the Clinical Outcome of Older Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Blood (2011) 118 (21): 1462.

https://doi.org/10.1182/blood.V118.21.1462.1462

Published: 2011

Journal Articles

Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute Myeloid Leukemia (AML)

Alison R. Walker, MD, Klaus H. Metzeler, MD, Susan Geyer, PhD, Heiko Becker, MD, Sebastian Schwind, MD, Susan P. Whitman, PhD, John Curfman, Yue-Zhong Wu, MS, Danilo Perrotti, MD, Ph.D, Rebecca B. Klisovic, MD, Ramiro Garzon, MD, William Blum, MD, Guido Marcucci, MD

Blood (2011) 118 (21): 944.

https://doi.org/10.1182/blood.V118.21.944.944

Published: 2011

Journal Articles

MLL-PTD Causes Hypomorph Condition of CBF Complex (RUNX1/CBFβ) and Predisposes the Abnormal Hematopoietic Stem and Progenitor Cells (HSPCs) to Clonal Expansion

Yue Zhang, Xiaomei Yan, Goro Sashida, MD, Xinghui Zhao, Yalan Rao, PhD, Susumu Goyama, MD, PhD, Susan P. Whitman, PhD, Nicholas Zorko, Kelsie M. Bernot, PhD, David Witte, MD, Qian-fei Wang, MD, Daniel G. Tenen, Zhijian Xiao, MD, Guido Marcucci, MD, James C. Mulloy, PhD, Michael A Caligiuri, MD, Gang Huang

Blood (2011) 118 (21): 2801.

https://doi.org/10.1182/blood.V118.21.2801.2801

Published: 2011

Journal Articles

Poor Outcome of RUNX1 -Mutated ( RUNX1 -mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures,

Blood (2011) 118 (21): 3454.

https://doi.org/10.1182/blood.V118.21.3454.3454

Published: 2011

Journal Articles

ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet ‘Favorable' Genetic Category

Blood (2011) 118 (21): 417.

https://doi.org/10.1182/blood.V118.21.417.417

Published: 2011

Journal Articles

Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts)

Blood (2011) 118 (21): 414.

https://doi.org/10.1182/blood.V118.21.414.414

Published: 2011

Journal Articles

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia

Sebastian Schwind, Guido Marcucci, Jessica Kohlschmidt, Michael D. Radmacher, Krzysztof Mrózek, Kati Maharry, Heiko Becker, Klaus H. Metzeler, Susan P. Whitman, Yue-Zhong Wu, Bayard L. Powell, Maria R. Baer, Jonathan E. Kolitz, Andrew J. Carroll, Richard A. Larson, Michael A. Caligiuri, Clara D. Bloomfield

Blood (2011) 118 (15): 4188–4198.

https://doi.org/10.1182/blood-2011-06-357764

Published: 2011

Includes: Supplemental data

Journal Articles

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Blood (2010) 116 (25): 5660–5669.

https://doi.org/10.1182/blood-2010-06-290536

Published: 2010

Includes: Supplemental data

NARROW

A Novel Regimen for Acute Myeloid Leukemia with MLL Partial Tandem Duplication: Results of a Phase 1 Study NCI 8485

Decitabine enhances anti-CD33 monoclonal antibody BI 836858–mediated natural killer ADCC against AML blasts

Eradicating acute myeloid leukemia in a Mll PTD/wt : Flt3 ITD/wt murine model: a path to novel therapeutic approaches for human disease

Differential Clinical Impact Of Gene Mutations and Their Combinations In Primary Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Decitabine Or 5-Azacitidine Pre-Treatment Does Not Compromise The Novel Fc-Engineered Antibody Mab 33.1-Mediated ADCC Against Primary AML Blasts - A Rationale For Combination Therapy

Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia

Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias

Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

MiR-3151 , a Novel MicroRNA Embedded in BAALC , Is Only Weakly Co-Expressed with Its Host Gene and Independently Impacts on the Clinical Outcome of Older Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute Myeloid Leukemia (AML)

MLL-PTD Causes Hypomorph Condition of CBF Complex (RUNX1/CBFβ) and Predisposes the Abnormal Hematopoietic Stem and Progenitor Cells (HSPCs) to Clonal Expansion

Poor Outcome of RUNX1 -Mutated ( RUNX1 -mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures,

ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet ‘Favorable' Genetic Category

Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts)

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only